title: RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation.
abstract: Recently, the rearrangement of RET proto-oncogene has been reported to be the most common genetic change in papillary thyroid carcinoma (PTC). However, its prevalence has been reported variably and its relation to clinical outcome has been controversial. The characteristic nuclear features of PTC usually render the diagnosis, but problem arises with equivocal cytologic features that are present focally. Although there remains some controversy, CK19 has been reported to be a useful ancillary tool for diagnosis of PTC. To evaluate the expression rate of RET/PTC rearrangement and CK19 in PTCs in a Korean population, we studied 115 papillary thyroid carcinomas in 3 mm-core tissue microarray based immunohistochemical analysis. The prevalence of Ret protein expression was 62.6% and the CK19 immunoreactivity was 80.9%. There was no statistically significant association between the Ret positivity and CK19 immunoreactivity, although the percent agreement of the two was relatively high. The clinicopathological variables did not correlate with the expression of Ret. In conclusion, the prevalence of Ret protein expression and its clinicopathological implications in a Korean population are not much different from those reported in previous studies. However, its detection via immunohistochemistry can be a useful diagnostic tool for diagnosing papillary thyroid carcinoma in conjunction with CK19.
authors.affiliation: Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Eunah
authors.initials: E
authors.lastname: Shin
authors.forename: Woung Youn
authors.initials: WY
authors.lastname: Chung
authors.forename: Woo Ick
authors.initials: WI
authors.lastname: Yang
authors.forename: Cheong Soo
authors.initials: CS
authors.lastname: Park
authors.forename: Soon Won
authors.initials: SW
authors.lastname: Hong
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000378:metabolism*; D000328:Adult; D002277:Carcinoma / Q000473:pathology; D045744:Cell Line, Tumor; D003593:Cytoplasm / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000096:biosynthesis*; D007723:Korea; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D015513:Oncogene Proteins / Q000096:biosynthesis*; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis*; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: C000715470:MAS1 protein, human; D015513:Oncogene Proteins; D000090063:Proto-Oncogene Mas; D007633:Keratins; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human; D020794:Receptor Protein-Tyrosine Kinases
references.citation: Virchows Arch. 1997 Dec;431(6):407-13
references.pmid: 9428928
references.citation: Virchows Arch. 1997 Jul;431(1):1-9
references.pmid: 9247627
references.citation: Am J Pathol. 1998 Nov;153(5):1443-50
references.pmid: 9811335
references.citation: Clin Endocrinol (Oxf). 1998 Sep;49(3):317-23
references.pmid: 9861322
references.citation: J Surg Oncol. 1999 Jun;71(2):76-81; discussion 81-2
references.pmid: 10389862
references.citation: Clin Cancer Res. 1998 Feb;4(2):287-94
references.pmid: 9516913
references.citation: J Clin Endocrinol Metab. 1998 May;83(5):1629-32
references.pmid: 9589668
references.citation: Thyroid. 1998 Jun;8(6):485-9
references.pmid: 9669285
references.citation: Hum Pathol. 1999 Oct;30(10):1166-71
references.pmid: 10534163
references.citation: Thyroid. 1999 Dec;9(12):1237-43
references.pmid: 10646664
references.citation: Am J Pathol. 2001 Apr;158(4):1245-51
references.pmid: 11290542
references.citation: Br J Surg. 2001 Apr;88(4):557-63
references.pmid: 11298625
references.citation: Mod Pathol. 2001 Apr;14(4):338-42
references.pmid: 11301350
references.citation: Am J Clin Pathol. 2001 Nov;116(5):696-702
references.pmid: 11710686
references.citation: Eur J Endocrinol. 2001 Nov;145(5):599-604
references.pmid: 11720878
references.citation: Histopathology. 2002 Sep;41(3):236-43
references.pmid: 12207785
references.citation: Surg Today. 2004;34(6):485-92
references.pmid: 15170542
references.citation: Am J Clin Pathol. 1989 Nov;92(5):654-8
references.pmid: 2479256
references.citation: Cell. 1990 Feb 23;60(4):557-63
references.pmid: 2406025
references.citation: Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1616-20
references.pmid: 1542652
references.citation: J Clin Invest. 1992 May;89(5):1517-22
references.pmid: 1569189
references.citation: Oncogene. 1992 Jul;7(7):1331-7
references.pmid: 1620547
references.citation: Jpn J Cancer Res. 1992 Jul;83(7):671-5
references.pmid: 1381340
references.citation: Cancer. 1994 Jan 1;73(1):176-80
references.pmid: 8275421
references.citation: Mod Pathol. 1994 Apr;7(3):295-300
references.pmid: 7520169
references.citation: Oncogene. 1995 Sep 21;11(6):1207-10
references.pmid: 7566982
references.citation: J Clin Endocrinol Metab. 1996 Sep;81(9):3360-5
references.pmid: 8784097
references.citation: Genes Chromosomes Cancer. 1996 May;16(1):1-14
references.pmid: 9162191
references.citation: J Clin Endocrinol Metab. 1997 Apr;82(4):1306-7
references.pmid: 9100614
references.citation: J Clin Endocrinol Metab. 1997 Jul;82(7):2322-8
references.pmid: 9215314
references.citation: J Pathol. 1998 May;185(1):71-8
references.pmid: 9713362